Aspirin for the primary prevention of cardiovascular disease a comprehensive review

Comprehensive Therapy

Volumn 31, Issue 3, 2005, Pages 186-193

  Rodondi, Nicolas ^a,b,d   Cornuz, Jacques ^b   Bauer, Douglas C ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG CONTRAINDICATION; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMORRHAGIC STROKE; HUMAN; MEDICAL DECISION MAKING; PRIMARY PREVENTION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKIN BRUISING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CEREBRAL HEMORRHAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL HEMORRHAGE; HUMANS; PATIENT PARTICIPATION; PRIMARY PREVENTION; RISK ASSESSMENT;

EID: 23844540673     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1385/COMP:31:3:186     Document Type: Review

References (67)

1. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998;97:1876-1887.
2. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388-391.
3. Goldman L, Phillips KA, Coxson P, et al. The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. J Am Coll Cardiol 2001;38:1012-1017.
4. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296:313-316.
5. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35.
6. Guide to Clinical Preventive Services. Report of the US Preventive Services Task Force; 2nd ed. Baltimore, Williams & Wilkins, 1996.
7. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-1762.
8. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357:89-95.
9. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351:233-241.
10. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352:1293-1304.
11. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-172.
12. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-271.
13. Rodondi N, Bauer DC. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events. Am J Med 2004;117:528-530.
14. Murphy M, Foster C, Nicholas JJ, Pignone M. Cardiovascular disorders. Primary prevention. Clin Evid 2003:154-187.
15. Aspirin Data Insufficient To Support Primary Prevention Of Heart Attack Indication. 2005 vol: FDA's Cardiovascular & Renal Drugs Advisory Committee; 2003. URL: www.fdaadvisorycommittee.com/FDC. Accessed January 16, 2005.
16. Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk of primary intracerebral haemorrhage associated with aspirin and nonsteroidal anti-inflammatory drugs: case-control study. BMJ 1999; 318:759-764.
17. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691.
18. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-160.
19. Lauer MS. Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med 2002;346:1468-1474.
20. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-1151.
21. Augustovski FA, Cantor SB, Thach CT, Spann SJ. Aspirin for primary prevention of cardiovascular events. J Gen Intern Med 1998;13:824-835.
22. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156:1829-1836.
23. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999;30:736-743.
24. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, et al. A prospective community-based study of stroke in Germany - the Erlangen Stroke Project (ESPro): incidence and case fatality at 1, 3, and 12 months. Stroke 1998;29:2501-2506.
25. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1993;24:796-800.
26. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health 1987;77:1417-1426.
27. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
28. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001;285:2486-2497.
29. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2000;23(Suppl 1):S61-S62.
30. Grundy SM. Primary prevention of coronary heart disease: integrating risk assessment with intervention. Circulation 1999;100:988-998.
31. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
32. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
33. Haq IU, Ramsay LE, Jackson PR, Wallis EJ. Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods. QJM 1999;92:379-385.
34. Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995;274:801-806.
35. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L. Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ 1995;310:975-978.
36. Risk Assessment Tool for Estimating 10-year Risk of Developing Hard CHD (Myocardial Infarction and Coronary Death): ATP III. http://www.nhlbi.nih.gov/ guidelines/cholesterol/index.htm.Last Accessed on February 28, 2005.
37. D'Agostino RB, Sr., Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-187.
38. Raine R, Streetly A, Davis AM. Variation in local policies and guidelines for cholesterol management: national survey. BMJ 1996;313:1368-1369.
39. Krein SL, Vijan S, Pogach LM, Hogan MM, Kerr EA. Aspirin use and counseling about aspirin among patients with diabetes. Diabetes Care 2002;25:965-970.
40. O'Connor PJ, Pronk NP, Tan AW, Rush WA, Gray RJ. Does professional advice influence aspirin use to prevent heart disease in an HMO population? Eff Clin Pract 1998;1:26-32.
41. Paragon JJ, Waite NM, Hobson EH, Seoldo N, VanAmburgh JA, Migden H. Improving aspirin prophylaxis in a primary care diabetic population. Pharmacotherapy 2003;23:73-79.
42. Stafford R, Ma J. Continued suboptimal use of aspirin in patients at high and moderate risk for CHD events. Proceedings of the 2004 Society of General Internal Medicine. 19 (S1) vol. Chicago: JGIM; 2004:19 (S1):133.
43. Cook NR, Chae C, Mueller FB, Landis S, Saks AM, Hennekens CH. Mismedication and under-utilization of aspirin in the prevention and treatment of cardiovascular disease. Med Gen Med 1999;22:E1.
44. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-2029.
45. Persell SD, Baker DW. Aspirin use among adults with diabetes: recent trends and emerging sex disparities. Arch Intern Med 2004;164:2492-2499.
46. Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 2001;24:197-201.
47. Meigs JB, Stafford RS. Cardiovascular disease prevention practices by U.S. Physicians for patients with diabetes. J Gen Intern Med 2000;15:220-228.
48. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006-2010.
49. Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000;321:13-17.
50. Wells PS, Forgie MA, Simms M, et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 2003;163:917-920.
51. Robinson A, Thomson RG. The potential use of decision analysis to support shared decision making in the face of uncertainty: the example of atrial fibrillation and warfarin anticoagulation. Qual Health Care 2000;9:238-244.
52. Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 2000;320:1380-1384.
53. Thomson R, Robinson A, Greenaway J, Lowe P. Development and description of a decision analysis based decision support tool for stroke prevention in atrial fibrillation. Qual Saf Health Care 2002;11:25-31.
54. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. Development of a decision aid for atrial fibrillation who are considering antithrombotic therapy. J Gen Intern Med 2000;15:723-730.
55. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993;35:219-226.
56. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996;348:1413-1416.
57. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343:16-22.
58. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154-160.
59. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. Jama 2002;288:2569-2578.
60. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama 2003;289:2560-2572.
61. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393.
62. Schildkraut JM, Myers RH, Cupples LA, Kiely DK, Kannel WB. Coronary risk associated with age and sex of parental heart disease in the Framingham Study. Am J Cardiol 1989;64:555-559.
63. Zanchetti A, Hansson L, Dahlof B, et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens 2002;20:2301-2307.
64. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993;13:161-165.
65. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293:699-706.
66. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000;85:169-182.
67. Daverat P, Castel JP, Dartigues JF, Orgogozo JM. Death and functional outcome after spontaneous intracerebral hemorrhage. A prospective study of 166 cases using multivariate analysis. Stroke 1991;22:1-6.